The GLP-1 boom has a dark side — even if serious complications are rare
By Ariana Eunjung Cha, Daniel Wu
Lawsuits raise a difficult question: When millions of people are taking new drugs, how much evidence of a devastating risk is enough to require a warning?
This story was published by The Washington Post. Read the full article on their site.
Read the full story at washingtonpost.com(opens in a new tab)





